Steroid-Free Quadruple Induction Regimen With Basiliximab, Everolimus, Mycophenolate and Very Low Dose Tacrolimus Compared to the Standard Triple Regimen in Patients with Kidney Allografts

Trial Profile

Steroid-Free Quadruple Induction Regimen With Basiliximab, Everolimus, Mycophenolate and Very Low Dose Tacrolimus Compared to the Standard Triple Regimen in Patients with Kidney Allografts

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Aug 2015

At a glance

  • Drugs Everolimus (Primary) ; Basiliximab; Mycophenolate mofetil; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top